After shaking up its leadership team, NuVasive could soon be undervalued if the company's progress continues upward, a Seeking Alpha analyst predicts.
What you should know:
1. While NuVasive declared that 2019 would be a reinvestment year, several analysts are looking favorably at the devicemaker's future.
"The shares look undervalued to me on both cash flow and revenue growth, and I believe the company is on its way toward fixing/resolving a lot of the issues that have caused problems over the last few years," the analyst wrote.
2. The analyst argued that NuVasive's past leadership team failed to fully recognize the changing spine market, especially concerning the slowdown caused by the rise of spinal stimulation devices and new technologies.
3. Despite the failings of the past leadership team, the analyst believes there is a light at the end of the tunnel. NuVasive CEO Chris Barry said the company would begin investing and developing new technologies, including the Pulse spine surgery automation system.
Read Seeking Alpha's entire analysis here.
More artilces on spine:
Zimmer Biomet replaces retiring CFO
Stryker expands overseas & more: 6 device company key notes
Pacira appoints former Johnson & Johnson exec Max Reinhardt president